This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Unversität Zürich. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Martin Schwill: Innovator in Cancer Therapy
Introduction
Martin Schwill is a prominent inventor based in Zurich, Switzerland. He has made significant contributions to the field of cancer therapy through his innovative research and development. His work focuses on creating targeted agents that can effectively combat cancer.
Latest Patents
Martin Schwill holds a patent for bispecific HER2 ligands for cancer therapy. This invention relates to a bispecific HER2-targeting agent that comprises a first polypeptide ligand binding to HER2 extracellular domain 1, a second polypeptide ligand binding to HER2 extracellular domain 4, and a linker covalently attaching the first polypeptide ligand to the second polypeptide ligand. This innovative approach aims to enhance the effectiveness of cancer treatments.
Career Highlights
Martin Schwill is affiliated with the University of Zurich, where he conducts his research and development activities. His work has garnered attention for its potential to improve cancer therapies and patient outcomes. With 1 patent to his name, he continues to push the boundaries of medical science.
Collaborations
Some of his notable coworkers include Rastislav Tamaskovic and Andreas Pluckthun. Their collaborative efforts contribute to the advancement of research in the field of cancer therapy.
Conclusion
Martin Schwill is a dedicated inventor whose work in bispecific HER2 ligands represents a significant advancement in cancer therapy. His contributions to the field are paving the way for more effective treatments and improved patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile